enGene
IPODetalimogene | Mainstreaming Non-Viral Gene Therapy for NMIBC
Public · Montreal, Canada · $17.9M raised
- Headquarters
- Montreal
- Employees
- 51–200
- Business Model
- B2B
- Website
- engene.com
- Total Funding
- $17.9M
- Last Round
- $11.5M Venture RoundJan 2018
- Rounds
- 3
- Type
- Public
About
enGene is a clinical-stage biotech pioneering non-viral gene therapy for non-muscle invasive bladder cancer and other mucosal tissue diseases.
Summary
enGene is a Biotech company based in Montreal, Canada. It has raised $17.9M in total across 3 rounds, most recently a $11.5M Venture Round round in Jan 2018. Investors include Adage Capital, Deerfield Management and Forbion Capital Partners.
Tech & App Stack
4 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Nov 2025
Sign up to see all 6 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...